

Fig.S1. Evolocumab and PCSK9 knockout alleviates neointimal hyperplasia by inhibiting proliferation and autophagy. (A) Immunohistochemistry of PCNA, Beclin1, p62 and LC3 after 14 days of in situ in ligated mouse common carotid arteries. The scale bar is 50 μm. (B) The quantifications of PCNA, Beclin1, p62 and LC3 levels after 14 days in the ligated mouse common carotid arteries (n = 3 mice for each group). Data are shown as mean ± SD (*p < 0.05, **p < 0.01, vs. sham group, two-way ANOVA followed by Tukey's multiple comparisons test). (C) Immunohistochemistry of PCNA, Beclin1, p62 and LC3 after 21 days of in situ in ligated mouse common carotid arteries. The scale bar is 50 μm. (D) The quantifications of PCNA, Beclin1, p62 and LC3 levels after 21 days in the ligated mouse common carotid arteries (n = 3 mice for each group). Data are shown as mean ± SD (*p < 0.05, **p < 0.01, vs. sham group, two-way ANOVA followed by Tukey's multiple comparisons test).



Fig.S2. Three Repetitions of Western blot analyses were conducted on carotid ligation *in vivo* model. Each group displays 2 biological replicates in each repetition.



Fig.S3. Two Repetitions of Western blot analyses were conducted on MOVAS cells treated with or without PDGF-BB. Each group displays 3 biological replicates in each repetition.



Fig.S4. Two Repetitions of Western blot analyses were conducted on MOVAS cells fortified with or without Evolocumab on the basis of PDGF-BB treatment. Each group displays 3 biological replicates in each repetition.



Fig.S5. Two Repetitions of Western blot analyses were conducted on MOVAS cells transfected with Contral or PCSK9 siRNA on the basis of PDGF-BB treatment. Each group displays 3 biological replicates in each repetition


si-NC
si-PCSK9
PDGF-BB + + + + + +
740 Y-P - - - - + +
p-PI3K
t-PI3K
p-AKT
t-AKT
p-mTOR
t-mTOR
PCNA
β-actin
Repetition 1


si-NC
si-PCSK9
PDGF-BB + + + + + +
740 Y-P - - - - + +
p-PI3K
t-PI3K
p-AKT
t-AKT
p-mTOR
t-mTOR
PCNA
β-actin
Repetition 2


si-NC
si-PCSK9
PDGF-BB + + + + + +
740 Y-P - - - - + +
p-PI3K
t-PI3K
p-AKT
t-AKT
p-mTOR
t-mTOR
PCNA
β-actin
Repetition 3

Fig.S6. Three Repetitions of Western blot analyses were conducted on MOVAS cells transfected with Contral or PCSK9 siRNA, and the cells were transfected with PCSK9 siRNA and intervened with PI3K agonist. Each group displays 2 biological replicates in each repetition.